Friday, September 2, 2011

Angioedima treatment new drug US FDA

Angioedima is a condition which causes spontaneous swelling of soft tissues dermis, subcutaneous tissue, submucosal tissues, mucosa, with typical symptoms of inflammation, swelling occurs typically over face and around throat, and tongue, it is painful and eatchy , some times blocking air way , which result in lowering oxygen level in blood (Asphyxia) , which may become life threatening if not treated.

Angioedima occure because of : Heredetory, Drug induced, because of allergy.
Angioedima caused by drug induced, because of allergy can be treated or ceases on discontinuation of causative agent or after treatment of antiallergic drug. Hearidetory angio edema , which is caused due to deficiency of C1 inhibitor protein , is treated with injecting intravenously C1-esterase (C1-inhibitor or C1INH) concentrate obtained from suitable donor blood, which is always not feasible.


Heredetory Angioedima HAE : Occur due to absence C1-inhibitor or partly or completely loss of capability to produce C1-inhibitor an ezyme which is responsible for inhibitory action on bradykinine which is responsible for process of inflammation , Bradykinin brings about vasodialation and is responsible for edematous condition, as vascular fluid keeps on accumulating in surrounding tissue which result in to edema.
US FDA has approved a new drug which can be used fro treatment of Angioedima, name of drug is Firazyr (icatibant) Injection which is approved for use in patients of age 18 and above.

Mode of action of Firazyr (icatibant):
Firazyr (icatibant) is a drug which resembles protein molecule (peptide), owing to its similarity to bradykinin peptide , it blocks bradykinin B2 receptors antagonistically , thereby reducing the edematous and inflammatory effect of bradykinin.

Other two drugs approved by US FDA for Heredetory Angioedima HAE
Berinert for facial HAE
Kalbitor for treating patients of age sixteen and above.

Side effects of Firazyr are as follows : Redening at the site of injection, increase in enzyme level in liver, fiver, rash, and dizziness. Shire Human Genetic Therapies Inc. of Cambridge, markets the drug Firazyr.

You may also like

Why Betalactam Antibiotics require a separate manufacturing aria in a pharmaceutical manufacturing company?

Chemistry behind the allergic reactions and mode of action of betalactum antibiotics

US FDA approved first oral drug to reduce Multiple Sclerosis MS relapses

US FDA limits dosage of acetaminophen to 325 mg per unit dosage form,Requires boxed warning on lables.

US FDA honours woman who rejected thalidomide and saved millions of children's from thalidomide

A Pharmaceutical exceipent Beta Cyclodextrin being used in a life saving treatment

Nanoparticles of insulin in place of painful injections in treatment for diabetes patients, transdermal , nasal drug delivery systems

Corifact becomes the first drug to treat congenital deficiency of Factor XII.

Protein which is responsible for cancer spread discovered An antisense RNA treatment or a drug could be designed to treat cancer efficiently and safely.

Novel Drugs: Cancer Chemotherapy Using Nanoparticles May Reduce Harmful Side Effects.

What is Nanotechnology, its applications in medicine and pharmaceuticals, drug developments?

Pharma sales jobs Find best pharmaceutical company Job

What is Therapeutic Index ?

What is Narrow Therapeutic Range Drug?

What is High Efficiency Particulate Air( HEPA ) filter ?

What is a Laminar Air Flow Cabinet.

What is an Isolator in pharmaceutical manufacturing.?

What is 21 CFR Part 11, US FDA compliance and CFR 21 Part 11?

CFR 21 part 11 and its application on computarised systems used in clinical trials US FDA guidelines
Pharmaceutical Validation

Types of validations in pharmaceutical manufacturing

Requirements of documents for validation of sterilisation process

Clean Room Classification

Find a Job in Pharmaceutical Company -->JOBS IN PHARMA INDUSTRY<---

Quality assurance in pharma industry

Quality by design concept for pharmaceutical industry

Quality by design concept in pharmaceutical industryan explanation

No comments: